Realbotix Charts New Course Through Merger with Onconetix

Realbotix plans a strategic merger with Onconetix, aiming for a Nasdaq listing. The deal will create an AI humanoid robotics leader, with Realbotix holding a controlling stake.

The robotics firm Realbotix is embarking on a fundamental strategic shift. In a move designed to solidify its position, the company plans to merge its subsidiary, Realbotix LLC, with Onconetix, creating a combined entity focused on AI-driven humanoid robotics that will trade on the Nasdaq. This transaction represents a pivotal restructuring for Realbotix, occurring amidst significant changes in its leadership and financial reporting.

Financial Reporting and Leadership in Transition

This merger announcement comes at a time of internal transition for Realbotix. The company has faced delays in submitting its audited financial statements for the 2025 fiscal year. These delays are attributed to a management change and health-related issues. Since January 2026, Scott Meyers has taken the helm as the new Chief Financial Officer to steer the company through this period.

Investor sentiment has been cautious. The stock currently trades around 0.17 euros, hovering near its 52-week low and reflecting a decline of approximately 41% since the start of the year. Technical analysis suggests the shares are deeply oversold, with the Relative Strength Index (RSI) registering a reading of 19.2.

The company has set a deadline of March 6, 2026, to file its outstanding financial reports. Concurrently, the merger with Onconetix is targeted for completion in the second half of 2026, pending the necessary regulatory and shareholder approvals.

Deal Structure and Strategic Control

The core of the agreement is a share-swap arrangement. Onconetix will acquire all outstanding shares of the robotics subsidiary. In return, upon closing the transaction, Realbotix's parent company is projected to hold a controlling stake of between 75% and 90% in the newly combined public company. The final percentage will be contingent on the cash balance held by Onconetix at the time of the merger.

To ensure strategic direction, Realbotix has secured the right to appoint four out of the five board members for the post-merger entity. The boards of directors for both companies have already given their approval. The deal now awaits consent from shareholders and regulatory bodies in the United States and Canada.